References

1. Mills, K.T.; Stefanescu, A.; He, J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 2020, 16, 223–237.
2. Jagannathan, R.; Patel, S.A.; Ali, M.K.; Narayan, K.M.V. Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors. Curr. Diabetes Rep. 2019, 19, 44.
3. Mahomed, F.A. On chronic Bright’s disease, and its essential symptoms. Lancet 1879, 1, 389–404.
4. Kahn, H.A.; Medalie, J.H.; Neufeld, H.N.; Riss, E.; Goldbourt, U. The incidence of hypertension and associated factors: The Israel ischemic heart disease study. Am. Heart J. 1972, 84, 171–182.
5. Grayson, P.C.; Kim, S.Y.; LaValley, M.; Choi, H.K. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res. 2011, 63, 102–110.
6. Selby, J.V.; Friedman, G.D.; Quesenberry, C.P. Precursors of Essential Hypertension: Pulmonary Function, Heart Rate, Uric Acid, Serum Cholesterol, and Other Serum Chemistries. Am. J. Epidemiol. 1990, 131, 1017–1027.
7. Hunt, S.C.; Stephenson, S.H.; Hopkins, P.N.; Williams, R.R. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991, 17, 969–976.
8. Jossa, F.; Farinaro, E.; Panico, S.; Krogh, V.; Celentano, E.; Galasso, R.; Mancini, M.; Trevisan, M. Serum uric acid and hypertension: The Olivetti heart study. J. Hum. Hypertens. 1994, 8, 677–681.
9. Dyer, A.R.; Liu, K.; Walsh, M.; Kiefe, C.; Jacobs, D.R., Jr.; Bild, D.E. Ten-year incidence of elevated blood pressure and its predictors: The CARDIA Study. J. Hum. Hypertens. 1999, 13, 13–21.
10. Taniguchi, Y.; Hayashi, T.; Tsumura, K.; Endo, G.; Fujii, S.; Okada, K. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J. Hypertens. 2001, 19, 1209–1215.
11. Nakanishi, N.; Okamoto, M.; Yoshida, H.; Matsuo, Y.; Suzuki, K.; Tatara, K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur. J. Epidemiol. 2002, 18, 523–530.
12. Nagahama, K.; Inoue, T.; Iseki, K.; Touma, T.; Kinjo, K.; Ohya, Y.; Takishita, S. Hyperuricemia as a Predictor of Hypertension in a Screened Cohort in Okinawa, Japan. Hypertens. Res. 2004, 27, 835–841.
13. Sundström, J.; Sullivan, L.; D’Agostino, R.B.; Levy, D.; Kannel, W.B.; Vasan, R.S. Relations of Serum Uric Acid to Longitudinal Blood Pressure Tracking and Hypertension Incidence. Hypertension 2005, 45, 28–33.
14. Perlstein, T.S.; Gumieniak, O.; Williams, G.H.; Sparrow, D.; Vokonas, P.S.; Gaziano, M.; Weiss, S.T.; Litonjua, A.A. Uric Acid and the Development of Hypertension. Hypertension 2006, 48, 1031–1036.
15. Mellen, P.B.; Bleyer, A.J.; Erlinger, T.P.; Evans, G.W.; Nieto, F.J.; Wagenknecht, L.E.; Wofford, M.R.; Herrington, D.M. Serum Uric Acid Predicts Incident Hypertension in a Biethnic Cohort. Hypertension 2006, 48, 1037–1042.
16. Shankar, A.; Klein, R.; Klein, B.E.K.; Nieto, F.J. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J. Hum. Hypertens. 2006, 20, 937–945.
17. Krishnan, E.; Kwoh, C.K.; Schumacher, H.R.; Kuller, L. Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome. Hypertension 2007, 49, 298–303.
18. Forman, J.P.; Choi, H.; Curhan, G.C. Plasma Uric Acid Level and Risk for Incident Hypertension Among Men. J. Am. Soc. Nephrol. 2006, 18, 287–292.
19. Kuwabara, M.; Hisatome, I.; Niwa, K.; Hara, S.; Roncal-Jimenez, C.A.; Bjornstad, P.; Nakagawa, T.; Andres-Hernando, A.; Sato, Y.; Jensen, T.; et al. Uric Acid Is a Strong Risk Marker for Developing Hypertension from Prehypertension: A 5-Year Japanese Cohort Study. Hypertension 2018, 71, 78–86.
20. Cicero, A.F.G.; Fogacci, F.; Giovannini, M.; Grandi, E.; D’Addato, S.; Borghi, C. Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension: Data from the Brisighella Heart Study. J. Hypertens. 2019, 37, 728–731.
21. Mazzali, M.; Hughes, J.; Kim, Y.-G.; Jefferson, J.A.; Kang, D.-H.; Gordon, K.L.; Lan, H.Y.; Kivlighn, S.; Johnson, R.J. Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism. Hypertension 2001, 38, 1101–1106.
22. Eräranta, A.; Kurra, V.; Tahvanainen, A.M.; Vehmas, T.I.; Kööbi, P.; Lakkisto, P.; Tikkanen, I.; Niemelä, O.J.; Mustonen, J.T.; Pörsti, I.H. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J. Hypertens. 2008, 26, 1661–1668.
23. Yang, X.; Gu, J.; Lv, H.; Li, H.; Cheng, Y.; Liu, Y.; Jiang, Y. Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor. Biomed. Pharmacother. 2019, 109, 1163–1170.
24. Zhang, J.; Diao, B.; Lin, X.; Xu, J.; Tang, F. TLR2 and TLR4 mediate an activation of adipose tissue renin-angiotensin system induced by uric acid. Biochimie 2019, 162, 125–133.
25. Corry, D.B.; Eslami, P.; Yamamoto, K.; Nyby, M.D.; Makino, H.; Tuck, M.L. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J. Hypertens. 2008, 26, 269–275.
26. Yu, M.A.; Sánchez-Lozada, L.G.; Johnson, R.J.; Kang, D.H. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J. Hypertens. 2010, 28, 1234–1242.
27. Mazzali, M.; Kanellis, J.; Han, L.; Feng, L.; Xia, Y.Y.; Chen, Q.; Kang, D.H.; Gordon, K.L.; Watanabe, S.; Nakagawa, T.; et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Ren. Physiol. 2002, 282, F991–F997.
28. Uedono, H.; Tsuda, A.; Ishimura, E.; Yasumoto, M.; Ichii, M.; Ochi, A.; Ohno, Y.; Nakatani, S.; Mori, K.; Uchida, J.; et al. Relationship between serum uric acid levels and intrarenal hemodynamic parameters. Kidney Blood Press. Res. 2015, 40, 315–322.
29. Sánchez-Lozada, L.G.; Tapia, E.; Santamaría, J.; Avila-Casado, C.; Soto, V.; Nepomuceno, T.; Rodríguez-Iturbe, B.; Johnson, R.J.; Herrera-Acosta, J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005, 67, 237–247.
30. Glantzounis, G.K.; Tsimoyiannis, E.C.; Kappas, A.M.; Galaris, D.A. Uric acid and oxidative stress. Curr. Pharm. Des. 2005, 11, 4145–4151.
31. Kanellis, J.; Watanabe, S.; Li, J.H.; Kang, D.H.; Li, P.; Nakagawa, T.; Wamsley, A.; Sheikh-Hamad, D.; Lan, H.Y.; Feng, L.; et al. Uric Acid Stimulates Monocyte Chemoattractant Protein-1 Production in Vascular Smooth Muscle Cells Via Mitogen-Activated Protein Kinase and Cyclooxygenase-2. Hypertension 2003, 41, 1287–1293.
32. Milanesi, S.; Verzola, D.; Cappadona, F.; Bonino, B.; Murugavel, A.; Pontremoli, R.; Garibotto, G.; Viazzi, F. Uric acid and angiotensin II additively promote inflammation and oxidative stress in human proximal tubule cells by activation of toll-like receptor 4. J. Cell Physiol. 2019, 234, 10868–10876.
33. Konukoglu, D.; Uzun, H. Endothelial Dysfunction and Hypertension. Adv. Exp. Med. Biol. 2017, 956, 511–540.
34. Yang, J.; Kamide, K.; Kokubo, Y.; Takiuchi, S.; Horio, T.; Matayoshi, T.; Yasuda, H.; Miwa, Y.; Yoshii, M.; Yoshihara, F.; et al. Assiciations of Hypertension and Its Complications with Variations in the Xanthine Dehydrogenase Gene. Hypertens. Res. 2008, 31, 931–940.
35. Wu, B.; Hao, Y.; Shi, J.; Geng, N.; Li, T.; Chen, Y.; Sun, Z.; Zheng, L.; Li, H.; Li, N.; et al. Association between xanthine dehydrogenase tag single nucleotide polymorphisms and essential hypertension. Mol. Med. Rep. 2015, 12, 5685–5690.
36. Scheepers, L.E.; Wei, F.F.; Stolarz-Skrzypek, K.; Malyutina, S.; Tikhonoff, V.; Thijs, L.; Salvi, E.; Barlassina, C.; Filipovský, J.; Casiglia, E.; et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: A population study. J. Hypertens. 2016, 34, 2147–2154.
37. Chaves, F.J.; Corella, D.; Blesa, S.; Mansego, M.L.; Marín, P.; Portoles, O.; Sorlí, J.V.; González-Albert, V.; Tormos, M.C.; García-García, A.B.; et al. Xanthine oxidoreductase polymorphisms: Influence in blood pressure and oxidative stress levels. Pharmacogenet. Genom. 2007, 17, 589–596.
38. Palmer, T.M.; Nordestgaard, B.G.; Benn, M.; Tybjærg-Hansen, A.; Davey Smith, G.; Lawlor, D.A.; Timpson, N.J. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ 2013, 347, f4262.
39. Yang, Q.; Köttgen, A.; Dehghan, A.; Smith, A.V.; Glazer, N.L.; Chen, M.-H.; Chasman, D.I.; Aspelund, T.; Eiriksdottir, G.; Harris, T.B.; et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ. Cardiovasc. Genet. 2010, 3, 523–530.
40. Mandal, A.K.; Mount, D.B. The Molecular Physiology of Uric Acid Homeostasis. Annu. Rev. Physiol. 2015, 77, 323–345.
41. Sanchez-Lozada, L.G.; Rodriguez-Iturbe, B.; Kelley, E.E.; Nakagawa, T.; Madero, M.; Feig, D.I.; Borghi, C.; Piani, F.; Cara-Fuentes, G.; Bjornstad, P.; et al. Uric acid and Hypertension: An Update with Recommendations. Am. J. Hypertens. 2020, 33, 583–594.
42. Stewart, D.J.; Langlois, V.; Noone, D. Hyperuricemia and Hypertension: Links and Risks. Integr. Blood Press. Control 2019, 12, 43–62.
43. Nigam, S.K.; Bhatnagar, V. The systems biology of uric acid transporters: The role of remote sensing and signaling. Curr. Opin. Nephrol. Hypertens. 2018, 27, 305–313.
44. Jalal, D.I.; Decker, E.; Perrenoud, L.; Nowak, K.L.; Bispham, N.; Mehta, T.; Smits, G.; You, Z.; Seals, D.; Chonchol, M.; et al. Vascular Function and Uric Acid-Lowering in Stage 3 CKD. J. Am. Soc. Nephrol. 2017, 28, 943–952.
45. Segal, M.S.; Srinivas, T.R.; Mohandas, R.; Shuster, J.J.; Wen, X.; Whidden, E.; Tantravahi, J.; Johnson, R.J. The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic. J. Am. Soc. Hypertens. 2015, 9, 610–619.
46. Kostka-Jeziorny, K.; Uruski, P.; Tykarski, A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press. 2011, 20, 104–110.
47. Borgi, L.; McMullan, C.; Wohlhueter, A.; Curhan, G.C.; Fisher, N.D.; Forman, J.P. Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension 2017, 69, 243–248.
48. McMullan, C.J.; Borgi, L.; Fisher, N.; Curhan, G.; Forman, J. Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial. Clin. J. Am. Soc. Nephrol. 2017, 12, 807–816.
49. Kimura, K.; Hosoya, T.; Uchida, S.; Inaba, M.; Makino, H.; Maruyama, S.; Ito, S.; Yamamoto, T.; Tomino, Y.; Ohno, I.; et al. Febuxostat Therapy for Patients with Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am. J. Kidney Dis. 2018, 72, 798–810.
50. Feig, D.I.; Soletsky, B.; Johnson, R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 2008, 300, 924–932.
51. Assadi, F. Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension. J. Nephrol. 2014, 27, 51–56.
52. Madero, M.; Rodríguez Castellanos, F.E.; Jalal, D.; Villalobos-Martín, M.; Salazar, J.; Vazquez-Rangel, A.; Johnson, R.J.; Sanchez-Lozada, L.G. A pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects: A randomized placebo controlled trial. J. Am. Soc. Hypertens. 2015, 9, 837–844.
53. Kim, H.A.; Seo, Y.I.; Song, Y.W. Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. J. Korean Med. Sci. 2014, 29, 1077–1081.
54. Gunawardhana, L.; McLean, L.; Punzi, H.A.; Hunt, B.; Palmer, R.N.; Whelton, A.; Feig, D.I. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects with Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study. J. Am. Heart Assoc. 2017, 6, e006683.
55. Soletsky, B.; Feig, D.I. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012, 60, 1148–1156.
56. Higgins, P.; Walters, M.R.; Murray, H.M.; McArthur, K.; McConnachie, A.; Lees, K.R.; Dawson, J. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: A randomised controlled trial. Heart 2014, 100, 1085–1092.
57. Kanbay, M.; Huddam, B.; Azak, A.; Solak, Y.; Kadioglu, G.K.; Kirbas, I.; Duranay, M.; Covic, A.; Johnson, R.J. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin. J. Am. Soc. Nephrol. 2011, 6, 1887–1894.
58. Johnson, R.J.; Choi, H.K.; Yeo, A.E.; Lipsky, P.E. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients with Chronic Gout. Hypertension 2019, 74, 95–101.
59. Tani, S.; Nagao, K.; Hirayama, A. Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study. Clin. Drug Investig. 2015, 35, 823–831.
60. Griebsch, A.; Zöllner, N. Effect of Ribomononucleotides Given Orally on Uric Acid Production in Man. In Purine Metabolism in Man. Advances in Experimental Medicine and Biology; Sperling, O., De Vries, A., Wyngaarden, J.B., Eds.; Springer: New York, NY, USA, 1974; pp. 443–449.
61. Harrison, R. Structure and function of xanthine oxidoreductase: Where are we now? Free Radic. Biol. Med. 2002, 33, 774–797.
62. So, A.; Thorens, B. Uric acid transport and disease. J. Clin. Investig. 2010, 120, 1791–1799.
63. Álvarez-Lario, B.; Macarrón-Vicente, J. Uric acid and evolution. Rheumatology 2010, 49, 2010–2015.
64. Xu, X.; Li, C.; Zhou, P.; Jiang, T. Uric acid transporters hiding in the intestine. Pharm. Biol. 2016, 54, 3151–3155.
65. Liu, H.; Zhuang, J.; Tang, P.; Li, J.; Xiong, X.; Deng, H. The Role of the Gut Microbiota in Coronary Heart Disease. Curr. Atheroscler. Rep. 2020, 22, 77.
66. Liu, X.; Lv, Q.; Ren, H.; Gao, L.; Zhao, P.; Yang, X.; Yang, G.; Xu, D.; Wang, G.; Yang, W.; et al. The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia. PeerJ 2020, 8, e8664.
67. Lu, C.; Li, Y.; Li, L.; Kong, Y.; Shi, T.; Xiao, H.; Cao, S.; Zhu, H.; Li, Z.; Zhou, Y. Alterations of Serum Uric Acid Level and Gut Microbiota After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in a Hyperuricemic Rat Model. Obes. Surg. 2020, 30, 1799–1807.
68. Kang, D.H.; Nakagawa, T.; Feng, L.; Watanabe, S.; Han, L.; Mazzali, M.; Truong, L.; Harris, R.; Johnson, R.J. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 2002, 13, 2888–2897.
69. Johnson, R.J.; Herrera-Acosta, J.; Schreiner, G.F.; Rodríguez-Iturbe, B. Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension. N. Engl. J. Med. 2002, 346, 913–923.
70. South, A.M.; Shaltout, H.A.; Nixon, P.A.; Diz, D.I.; Jensen, E.T.; O’Shea, T.M.; Chappell, M.C.; Washburn, L.K. Association of circulating uric acid and angiotensin-(1–7) in relation to higher blood pressure in adolescents and the influence of preterm birth. J. Hum. Hypertens. 2020, 34, 818–825.
71. De Becker, B.; Coremans, C.; Chaumont, M.; Delporte, C.; Van Antwerpen, P.; Franck, T.; Rousseau, A.; Zouaoui Boudjeltia, K.; Cullus, P.; van de Borne, P. Severe Hypouricemia Impairs Endothelium-Dependent Vasodilatation and Reduces Blood Pressure in Healthy Young Men: A Randomized, Placebo-Controlled, and Crossover Study. J. Am. Heart Assoc. 2019, 8, e013130.
72. Milicević, Z.; Jelaković, B.; Marinković, M. Hyperuricemia and plasma renin activity in essential arterial hypertension. Lijec. Vjesn. 1994, 116, 14–17.
73. Mulè, G.; Castiglia, A.; Morreale, M.; Geraci, G.; Cusumano, C.; Guarino, L.; Altieri, D.; Panzica, M.; Vaccaro, F.; Cottone, S. Serum uric acid is not independently associated with plasma renin activity and plasma aldosterone in hypertensive adults. Nutr. Metab. Cardiovasc. Dis. 2017, 27, 350–359.
74. Perlstein, T.S.; Gumieniak, O.; Hopkins, P.N.; Murphey, L.J.; Brown, N.J.; Williams, G.H.; Hollenberg, N.K.; Fisher, N.D. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int. 2004, 66, 1465–1470.
75. Kiuchi, M.G.; Chen, S.; Carnagarin, R.; Schlaich, M.P. The role of afferent renal denervation in renovascular hypertension-another brick in the wall. Pflug. Arch. 2020, 472, 323–324.
76. Herrmann, S.M.; Textor, S.C. Renovascular Hypertension. Endocrinol. Metab. Clin. North Am. 2019, 48, 765–778.
77. Kırça, M.; Oğuz, N.; Çetin, A.; Uzuner, F.; Yeşilkaya, A. Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. J. Recept. Signal Transduct. 2017, 37, 167–173.
78. Kang, D.H.; Han, L.; Ouyang, X.; Kahn, A.M.; Kanellis, J.; Li, P.; Feng, L.; Nakagawa, T.; Watanabe, S.; Hosoyamada, M.; et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am. J. Nephrol. 2005, 25, 425–433.
79. Romi, M.M.; Arfian, N.; Tranggono, U.; Setyaningsih, W.A.W.; Sari, D.C.R. Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. BMC Nephrol. 2017, 18, 326.
80. Piani, F.; Johnson, R.J. Does gouty nephropathy exist, and is it more common than we think? Kidney Int. 2021, 99, 31–33.
81. Khanna, P.; Johnson, R.J.; Marder, B.; LaMoreaux, B.; Kumar, A. Systemic Urate Deposition: An Unrecognized Complication of Gout? J. Clin. Med. 2020, 3, 3204.
82. Lee, J.H.; Go, T.H.; Lee, S.H.; Kim, J.; Huh, J.H.; Kim, J.Y.; Kang, D.R.; Jeong, S.; Koh, S.B.; Choi, J.R. Association between Serum Urate and Risk of Hypertension in Menopausal Women with XDH Gene. J. Clin. Med. 2019, 23, 738.
83. Nishio, S.; Maruyama, Y.; Sugano, N.; Hosoya, T.; Yokoo, T.; Kuriyama, S. Gender interaction of uric acid in the development of hypertension. Clin. Exp. Hypertens. 2018, 40, 446–451.
84. Major, T.J.; Dalbeth, N.; Stahl, E.A.; Merriman, T.R. An update on the genetics of hyperuricaemia and gout. Nat. Rev. Rheumatol. 2018, 14, 341–353.
85. Kei, A.; Koutsouka, F.; Makri, A.; Elisaf, M. Uric acid and cardiovascular risk: What genes can say. Int. J. Clin. Pract. 2018, 72, e13048.
86. Zheng, Y.; Ning, C.; Zhang, X.; Zhao, Y.; Li, Y.; Qian, L.; Li, J.; Fang, Z. Association Between ALDH-2 rs671 and Essential Hypertension Risk or Blood Pressure Levels: A Systematic Review and Meta-Analysis. Front. Genet. 2020, 15, 685.
87. Cicero, A.; Fogacci, F.; Cincione, R.I.; Tocci, G.; Borghi, C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med. Princ. Pract. 2020.
88. Yoshida, S.; Kurajoh, M.; Fukumoto, S.; Murase, T.; Nakamura, T.; Yoshida, H.; Hirata, K.; Inaba, M.; Emoto, M. Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry. Sci. Rep. 2020, 10, 4437.
89. Lanaspa, M.A.; Kuwabara, M.; Andres-Hernando, A.; Li, N.; Cicerchi, C.; Jensen, T.; Orlicky, D.J.; Roncal-Jimenez, C.A.; Ishimoto, T.; Nakagawa, T.; et al. High salt intake causes leptin resistance and obesity in mice by stimulating endogenous fructose production and metabolism. Proc. Natl. Acad. Sci. USA 2018, 20, 3138–3143.
90. Todd, A.S.; Walker, R.J.; MacGinley, R.J.; Kelly, J.; Merriman, T.R.; Major, T.J.; Johnson, R.J. Dietary Sodium Modifies Serum Uric Acid Concentrations in Humans. Am. J. Hypertens. 2017, 6, 1196–1202.
91. Feig, D.I.; Kang, D.H.; Johnson, R.J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008, 359, 1811–1821.
92. Syamala, S.; Li, J.; Shankar, A. Association between serum uric acid and prehypertension among US adults. J. Hypertens. 2007, 25, 1583–1589.
93. Jiang, M.; Gong, D.; Fan, Y. Serum uric acid levels and risk of prehypertension: A meta-analysis. Clin. Chem. Lab. Med. 2017, 55, 314–321.
94. Kleber, M.E.; Delgado, G.; Grammer, T.B.; Silbernagel, G.; Huang, J.; Krämer, B.K.; Ritz, E.; März, W. Uric Acid and Cardiovascular Events: A Mendelian Randomization Study. J. Am. Soc. Nephrol. 2015, 26, 2831–2838.
95. Cicero, A.; Fogacci, F.; Kuwabara, M.; Borghi, C. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina 2021, 57, 58.
96. Wang, L.; Zhang, T.; Liu, Y.; Tang, F.; Xue, F. Association of Serum Uric Acid with Metabolic Syndrome and Its Components: A Mendelian Randomization Analysis. Biomed. Res. Int. 2020, 2020, 6238693.
97. Li, X.; Meng, X.; Timofeeva, M.; Tzoulaki, I.; Tsilidis, K.K.; Ioannidis, J.P.; Campbell, H.; Theodoratou, E. Serum uric acid levels and multiple health outcomes: Umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ 2017, 357, j2376.
98. Gondouin, B.; Jourde-Chiche, N.; Sallee, M.; Dou, L.; Cerini, C.; Loundou, A.; Morange, S.; Berland, Y.; Burtey, S.; Brunet, P.; et al. Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels. Nephron 2015, 131, 167–174.
99. Kim, Y.J.; Oh, S.H.; Ahn, J.S.; Yook, J.M.; Kim, C.D.; Park, S.H.; Cho, J.H.; Kim, Y.L. The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia. Int. J. Mol. Sci. 2020, 21, 7444.
100. Milojkovic, B.; Kocic, G.; Radenkovic, S.; Pavlovic, R.; Cvetkovic, T.; Deljanin-Ilic, M.; Ilic, S.; Milojkovic, D.B.; Djindjic, B.; Stojanovic, D.; et al. Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Ren. Fail. 2014, 36, 613–618.
101. Bove, M.; Cicero, A.F.; Veronesi, M.; Borghi, C. An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia. Vasc. Health Risk Manag. 2017, 13, 23–28.
102. Li, Q.; Li, X.; Wang, J.; Liu, H.; Kwong, J.S.; Chen, H.; Li, L.; Chung, S.C.; Shah, A.; Chen, Y.; et al. Diagnosis and treatment for hyperuricemia and gout: A systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019, 9, e026677.
103. Choi, H.K.; Soriano, L.C.; Zhang, Y.; Rodríguez, L.A. Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study. BMJ 2012, 344, d8190.
104. Tseng, W.C.; Chen, Y.T.; Ou, S.M.; Shih, C.J.; Tarng, D.C. Taiwan Geriatric Kidney Disease (TGKD) Research Group. U-Shaped Association Between Serum Uric Acid Levels with Cardiovascular and All-Cause Mortality in the Elderly: The Role of Malnourishment. J. Am. Heart Assoc. 2018, 10, e007523.
105. Masi, S.; Georgiopoulos, G.; Alexopoulos, G.; Pateras, K.; Rosada, J.; Seravalle, G.; De Ciuceis, C.; Taddei, S.; Borghi, C.; Grassi, G.; et al. The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. J. Clin. Med. 2020, 9, 2027.
106. Ueno, S.; Hamada, T.; Taniguchi, S.; Ohtani, N.; Miyazaki, S.; Mizuta, E.; Ohtahara, A.; Ogino, K.; Yoshida, A.; Kuwabara, M.; et al. Effect of Antihypertensive Drugs on Uric Acid Metabolism in Patients with Hypertension: Cross-Sectional Cohort Study. Drug Res. 2016, 66, 628–632.
107. Rubio-Guerra, A.F.; Garro-Almendaro, A.K.; Elizalde-Barrera, C.I.; Suarez-Cuenca, J.A.; Duran-Salgado, M.B. Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients. Ther. Adv. Cardiovasc. Dis. 2017, 11, 57–62.
108. Høieggen, A.; Alderman, M.H.; Kjeldsen, S.E.; Julius, S.; Devereux, R.B.; De Faire, U.; Fyhrquist, F.; Ibsen, H.; Kristianson, K.; Lederballe-Pedersen, O.; et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004, 65, 1041–1049.
109. Alderman, M.; Aiyer, K.J. Uric acid: Role in cardiovascular disease and effects of losartan. Curr. Med. Res. Opin. 2004, 20, 369–379.
110. Krajčoviechová, A.; Wohlfahrt, P.; Bruthans, J.; Šulc, P.; Lánská, V.; Eremiášová, L.; Pudil, J.; Linhart, A.; Filipovský, J.; Mayer, O.; et al. Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population? J. Clin. Hypertens. 2020, 22, 897–905.
111. Virdis, A.; Masi, S.; Casiglia, E.; Tikhonoff, V.; Cicero, A.F.G.; Ungar, A.; Rivasi, G.; Salvetti, M.; Barbagallo, C.M.; Bombelli, M.; et al. Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension 2020, 75, 302–308.
112. Maloberti, A.; Giannattasio, C.; Bombelli, M.; Desideri, G.; Cicero, A.F.G.; Muiesan, M.L.; Rosei, E.A.; Salvetti, M.; Ungar, A.; Rivasi, G.; et al. Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press. Cardiovasc. Prev. 2020, 27, 121–128.
113. Robinson, P.C.; Dalbeth, N. Advances in pharmacotherapy for the treatment of gout. Expert Opin. Pharmacother. 2015, 16, 533–546.
114. Iwatani, M.; Wasada, T.; Katsumori, K.; Watanabe-Takahashi, C.; Kamatani, N.; Iwamoto, Y. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics. Diabetologia 2000, 43, 814–815.
115. Derosa, G.; Maffioli, P.; Sahebkar, A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol. Res. 2015, 102, 63–70.
116. Forman, J.P.; Choi, H.; Curhan, G.C. Uric acid and insulin sensitivity and risk of incident hypertension. Arch. Int. Med. 2009, 169, 155–162.